How to buy GH Research stock (GH Research)

GH Research is a biotechnology business based in the US. GH Research shares (GHRS) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $7.30 – an increase of 6.57% over the previous week. GH Research employs 49 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy GH Research stock

Buy GH Research stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

GH Research stock price (NASDAQ: GHRS)

Use our graph to track the performance of GHRS stocks over time.

GH Research shares at a glance

• Key figures

Information last updated 2024-12-26.

Latest market close	$7.30
52-week range	$5.12 - $14.99
50-day moving average more info button	$8.38
200-day moving average more info button	$10.18
Wall St. target price	$31.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.79

Is it a good time to buy GH Research stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

GH Research price performance over time

Historical closes compared with the close of $7.09 from 2024-12-24

1 week (2024-12-20)	3.50%
1 month (2024-11-27)	-23.60%
3 months (2024-09-27)	3.05%
6 months (2024-06-27)	-40.87%

1 year (2023-12-27)	28.91%
2 years (2022-12-27)	-33.18%
3 years (2021-12-27)	23.71
5 years (2019-12-23)	N/A

GH Research financials

Gross profit TTM	$0
Return on assets TTM	-12.74%
Return on equity TTM	-16.2%
Profit margin	0%
Book value	$4.21
Market Capitalization more info button	$368.9 million

TTM: trailing 12 months

GH Research share dividends

We're not expecting GH Research to pay a dividend over the next 12 months.

You may also wish to consider:

• Pfizer (PFE.US) (6.53% forward annual dividend yield)
• Bristol-Myers Squibb Company (BMY.US) (4.33% forward annual dividend yield)

GH Research share price volatility

Over the last 12 months, GH Research's shares have ranged in value from as little as $5.12 up to $14.99. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while GH Research's is 0.741. This would suggest that GH Research's shares are less volatile than average (for this exchange).

To put GH Research's beta into context you can compare it against those of similar companies.

• Pfizer (PFE.US): 0.615
• Moderna (MRNA.US): 1.69
• Bristol-Myers Squibb Company (BMY.US): 0.441

GH Research overview

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland. .

Frequently asked questions

null
What percentage of GH Research is owned by insiders or institutions?
Currently 40.387% of GH Research shares are held by insiders and 59.154% by institutions. How many people work for GH Research?
Latest data suggests 49 work at GH Research. When does the fiscal year end for GH Research?
GH Research's fiscal year ends in December. Where is GH Research based?
GH Research's address is: Joshua Dawson House, Dublin, Ireland, D02 RY95 What is GH Research's ISIN number?
GH Research's international securities identification number is: IE000GID8VI0